SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Wells Fargo Sets $35 Price Target for Denali Therapeutics

Benzinga reports that Wells Fargo initiated coverage of Denali Therapeutics at Overweight.

DNLI

Related stories